Beijing Inno Medicine Co., Ltd.

This study tests whether adding YN001 to standard cholesterol-lowering therapy can reduce plaque in heart arteries. About 24 adults with coronary atherosclerosis and at least one blocked artery will receive YN001 intravenously. The main goal is to see changes in plaque volume and…

This early-stage study is testing a new drug called YN001 in 24 healthy adults aged 18 to 65. The goal is to measure how the drug moves through the body, how long it stays, and whether it causes any side effects. Participants receive a single dose and are monitored closely. This …